Navigation Links
Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
Date:1/3/2012

ELKRIDGE, Md., Jan. 3, 2012 /PRNewswire/ -- GP Strategies Corporation (NYSE: GPX), a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services, today announced that Sagard Capital Partners, L.P. ("Sagard Capital") has agreed to purchase 350,000 shares in a private transaction from Bedford Oak Partners, L.P. The closing of the transaction is subject to customary conditions and is expected to occur within the next week (but in any event prior to January 13th). This purchase increases Sagard Capital's ownership to 3,333,621 shares or 17.8% of GP Strategies' outstanding common stock.  GP Strategies is not a participant in the transaction.

(Logo:  http://photos.prnewswire.com/prnh/20110404/MM77341LOGO-b )

"We are extremely pleased that an investor like Sagard Capital continues to share our vision on the two-year anniversary of their original private placement.  We view their increased investment as a tangible sign of continued confidence in the direction of GP Strategies," commented Scott N. Greenberg, Chief Executive Officer of GP Strategies.

"We remain enthusiastic about our investment in GP Strategies.  GP Strategies has truly become a leading provider of custom training, consulting and technical services by building a foundation of strong global relationships with their clients," said Dan Friedberg, Managing Partner of Sagard Capital Partners, L.P.  Dan Friedberg is on the Board of Directors and Executive Committee of GP Strategies.

Bedford Oak Partners, L.P., for reasons of its own internal liquidity, decided to sell its shares in GP Strategies before the 2011 calendar year end. Harvey P. Eisen, Chairman of the Board of GP Strategies since April 2005, is also the Chairman and Managing Member of Bedford Oak Advisors, LLC, the investment manager of Bedford Oak Partners, L.P. 

About Sagard Capital Partners, L.P.

Sagard Capital is a long-term impact investor in public and private small and mid-sized companies.  Sagard is an evergreen fund with an indefinite holding period for its investments.  Sagard specializes in flexible transaction structures, making minority investments with equity or debt to best address a company's needs.  Sagard partners with management teams committed to driving long-term shareholder value, through a combination of capital, a global network of relationships, and a team built to deliver value-add support.  Additional information may be found at www.sagardcapital.com.

About GP Strategies

GP Strategies, a NYSE-listed company (GPX), is a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services.  GP Strategies' solutions improve the effectiveness of organizations by delivering innovative and superior training, consulting and business improvement services, customized to meet the specific needs of its clients.  Clients include Fortune 500 companies, manufacturing, process and energy industries, and other commercial and government customers.  Additional information may be found at www.gpstrategies.com.

Forward Looking Statements

We make statements in this press release that are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements reflect our current expectations concerning future events and results. We use words such as "expect," "intend," "believe," "may," "should," "could," "anticipates," and similar expressions to identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These statements are not guarantees of our future performance and are subject to risks, uncertainties, and other important factors that could cause our actual performance or achievements to be materially different from those we project. For a full discussion of these risks, uncertainties, and factors, we encourage you to read our documents on file with the Securities and Exchange Commission, including those set forth in our periodic reports under the forward-looking statements and risk factors sections. Except as required by law, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE GP Strategies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
6. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
7. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
8. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
9. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
10. New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers
11. Accumetrics Announces $16.5M in New Capital Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt the ... overall productivity and performance in the workplace. The goal of Clearview Resolution Services has ... weeks of April, Clearview Resolution Services will be shutting down the office early on ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
Breaking Medicine News(10 mins):